Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:18 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia
NCT03511521 · Northwestern University · PHASE4 · terminated · last registry update 2020-09-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Unable to recruit sufficient number of patients” | – | Registry record, Northwestern University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against INSR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-08-19Phase 3 first posted: Novo Nordisk A/S, IcoSema + Insulin glargine (NCT05013229)
- 2021-08-18Results posted on the registry: The University of Texas Health Science Center, Houston, Neutral Protamine Hagedorn (NPH) + Detemir insulin (NCT03620890)
- 2021-08-04Results posted on the registry: Albert Einstein College of Medicine, Exenatide + Rapid and long acting insulin (NCT01269034)
- 2021-07-23Phase 3 first posted: Mannkind Corporation, Afrezza + Rapid-acting Insulin Analog (NCT04974528)
- 2021-07-09Phase 3 first posted: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Insulin degludec injection + Tresiba® (NCT04955834)
- 2021-05-17Also stopped (terminated): Hennepin Healthcare Research Institute, Degludec + Standard long-acting (NCT03001323)
- 2021-05-11Phase 3 first posted: Novo Nordisk A/S, Insulin icodec + Insulin glargine (NCT04880850)
- 2021-04-19Phase 3 first posted: Novo Nordisk A/S, insulin icodec + insulin degludec (NCT04848480)
- 2021-03-12Phase 3 first posted: Novo Nordisk A/S, Insulin icodec + Placebo insulin icodec (NCT04795531)
- 2021-03-08Results posted on the registry: Eli Lilly and Company, LY3209590 + Insulin Degludec (NCT03736785)
- 2021-02-25Phase 3 first posted: Novo Nordisk A/S, Insulin degludec + Insulin Icodec (NCT04770532)
- 2021-02-18Phase 3 first posted: Novo Nordisk A/S, Insulin icodec + Insulin Glargine 100U/mL (NCT04760626)
- 2021-02-01Results posted on the registry: Novo Nordisk A/S, Insulin icodec + Placebo (insulin 287) (NCT03751657)
- 2021-01-25Results posted on the registry: East Coast Institute for Research, a drug against INSR (NCT03495908)
- 2021-01-12Results posted on the registry: Novo Nordisk A/S, Insulin degludec + Insulin glargine (NCT03687827)
- 2021-01-08Results posted on the registry: Novo Nordisk A/S, Insulin icodec + Insulin glargine U100 (NCT03922750)
- 2021-01-08Results posted on the registry: Novo Nordisk A/S, Insulin icodec + Insulin Glargine (NCT03951805)
- 2020-11-10Results posted on the registry: University of California, San Francisco, GLP1 receptor agonist + basal insulin (NCT02846233)
- 2020-10-19Phase 3 first posted: Novo Nordisk A/S, Faster aspart + Insulin aspart (NCT04588259)
- 2020-09-28Results posted on the registry: University of Guadalajara, Insulin Degludec + Insulin Glargine (NCT02680457)
- 2020-07-08Phase 3 first posted: Novo Nordisk A/S, Insulin icodec + Insulin glargine (NCT04460885)
- 2020-07-07Results posted on the registry: Novo Nordisk A/S, Insulin degludec/liraglutide + Insulin degludec (NCT03172494)
- 2020-06-09Also stopped (terminated): Weill Cornell Medical College in Qatar, Insulin Degludec U100 + Insulin Glargine (NCT03349840)
- 2020-05-07Results posted on the registry: Emory University, Glargine U300 + Glargine U100 (NCT03013985)
- 2020-05-01Results posted on the registry: Eli Lilly and Company, LY900014 + Insulin Lispro (NCT03214367)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision